The US Medicaid program is emphasizing that Biogen, Inc./Eisai Co., Ltd.’s Aduhelm (aducanumab) for Alzheimer’s disease must be a covered outpatient drug as the manufacturer has a drug rebate agreement with the program.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?